Black Hawk, Vesicor enter forward purchase agreement with Meteora for 1.35M shares
- Black Hawk Acquisition Corp and Vesicor Therapeutics signed a forward purchase agreement with Meteora on September 22, 2026
- The agreement covers up to 1,350,000 shares, comprising recycled and additional shares
- Black Hawk will domesticate as a Delaware corporation and rename to Vesicor Therapeutics Holdings, Inc.
- The initial reset price for the forward transaction is set at $10.00 per share
- Prepayment amounts from the trust account are reduced by the cost of any additional shares purchased by Meteora
*this image is generated using AI for illustrative purposes only.
Black Hawk Acquisition Corporation and Vesicor Therapeutics, Inc. entered into a forward purchase agreement with Meteora Select Trading Opportunities Master, LP on September 22, 2026. The deal covers up to 1,350,000 shares in connection with the company’s business combination.
Under the OTC Equity Prepaid Forward Transaction confirmation, the shares may consist of Recycled Shares purchased by Meteora from third parties or Additional Shares purchased directly from the company. The aggregate number of these shares cannot exceed the maximum limit of 1.35 million.
Domestication and name change
As part of the Business Combination Agreement dated April 26, 2025, Black Hawk Acquisition Corporation will domesticate as a Delaware corporation. The entity will change its name to Vesicor Therapeutics Holdings, Inc. Vesicor Therapeutics, Inc. will become a wholly owned subsidiary of the new public company.
Pricing and payment mechanics
The initial price under the agreement equals the per-share redemption price payable to holders of public ordinary shares during the business combination. At closing, the company will pay Meteora a prepayment amount from the trust account. This amount is calculated as the number of shares specified in the pricing date notice multiplied by the Initial Price, reduced dollar-for-dollar by the purchase price funded by Meteora for any Additional Shares.
The reset price is initially set at $10.00 per share. This figure may be reduced by mutual written agreement or upon certain dilutive offerings.
| Term | Detail |
|---|---|
| Counterparty | Meteora Select Trading Opportunities Master, LP |
| Maximum Shares | 1,350,000 |
| Initial Reset Price | $10.00 per share |
| Agreement Date | September 22, 2026 |
What the Numbers Show
The structure of the prepayment amount creates a direct offset between trust account outflows and new capital injection. By reducing the prepayment dollar-for-dollar by the purchase price of Additional Shares, the company effectively nets the cash impact of Meteora’s direct investment against the redemption obligation. This mechanism ensures that Meteora’s total exposure remains capped at the value of the forward contract while allowing the company to retain cash equivalent to the additional equity purchased.
How will the Delaware domestication and name change impact Vesicor Therapeutics' eligibility for listing on major exchanges like Nasdaq or NYSE?
What specific clinical milestones must Vesicor Therapeutics achieve to justify the $10.00 reset price if the stock trades below this level?
How might Meteora's involvement as a forward purchaser influence institutional investor sentiment during the upcoming shareholder vote for the business combination?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
